Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | MMP9 | P14780 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038292 | 0.89 | TGM2 (0.42) | TGM2FOLH1MMP2MMP9CA1 | |
| SCHEMBL6862744 | 0.89 | TGM2 (0.42) | TGM2FOLH1MMP2MMP9CA1 | |
| SCHEMBL6139503 | 0.83 | DPP8 (0.51) | TGM2FOLH1MMP2MMP9MMP1 | |
| SCHEMBL5035365 | 0.82 | TGM2 (0.45) | TGM2CPB1CPB2 | |
| SCHEMBL6139547 | 0.76 | FOLH1 (0.36) | TGM2FOLH1 | |
| SCHEMBL6139590 | 0.74 | FOLH1 (0.37) | TGM2FOLH1 | |
| SCHEMBL6139383 | 0.74 | TGM2 (0.42) | TGM2FOLH1MMP2MMP9CA1 | |
| SCHEMBL6139777 | 0.74 | CASP1 (0.39) | TGM2 | |
| SCHEMBL5038355 | 0.72 | GLP1R (0.33) | CA1CA2CPB2 | |
| SCHEMBL29072085 | 0.68 | FOLH1 (0.76) | FOLH1MMP2MMP9CPB1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307237-B9 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1307237-B1 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| US-6676928-B2 | AS CONTRAST MEDIA FOR THE VISUALIZATION OF MALIGNANT TUMORS, LYMPH NODES AND NECROTIC TISSUE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| EP-1307236-A2 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MR-IMAGING FOR THE REPRESENTATION OF PLAQUES, TUMOURS AND NECROSES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-07 | — | — | EP | disclosed |
| EP-1307237-A2 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-07 | — | — | EP | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | SCHERING AG (DE) | 2002-06-20 | — | — | US | disclosed |
| WO-2002013875-A2 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002013874-A2 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MR-IMAGING FOR THE REPRESENTATION OF PLAQUES, TUMOURS AND NECROSES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | TGM2 3578/4885FOLH1 2668/4885MMP2 2091/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | TGM2 3746/4885FOLH1 3271/4885MMP2 2320/4885 |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | FFAR1, FGB, FCGRT | TGM2 2391/4885FOLH1 2292/4885MMP2 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.